Search

RU-2861561-C2 - USES OF MICROBIOME COMPOSITIONS

RU2861561C2RU 2861561 C2RU2861561 C2RU 2861561C2RU-2861561-C2

Abstract

FIELD: biotechnology. SUBSTANCE: disclosed is the use of a composition comprising from 10 1 to 10 15 CFU of each of Gluconacetobacter hansenii , Terrisporobacter glycolicus , Coprococcus sp. , Lactobacillus plantarum , Clostridium butyricum , Paenibacillus sp. , Veillonella sp. , Bifidobacterium sp. , Bacillus subtilis and Acidaminococcus sp ., for modulating one or more metabolites in a subject, wherein said composition is suitable for consumption by a mammal. Also described is the use of a composition comprising from 10 1 to 10 15 CFU of each of seven or more of Gluconacetobacter hansenii , Terrisporobacter glycolicus , Coprococcus sp. , Lactobacillus plantarum , Clostridium butyricum , Paenibacillus sp. , Veillonella sp. , Bifidobacterium sp. , Bacillus subtilis and Acidaminococcus sp. , for modulating one or more metabolites in a subject. EFFECT: use of a composition of specific bacteria for modulating the metabolome in a subject. 12 cl, 14 dwg, 8 tbl, 5 ex

Inventors

  • GOVINDAN, Dzhoti Amaranat
  • DZHAYAMANI, Elampariti
  • CHATTER, Priti KH.
  • CHATTER, MUKESH

Dates

Publication Date
20260506
Application Date
20210910
Priority Date
20200911

Claims (18)

  1. 1. The use of a composition comprising from 10 1 to 10 15 CFU of each of Gluconacetobacter hansenii , Terrisporobacter glycolicus , Coprococcus sp. , Lactobacillus plantarum , Clostridium butyricum , Paenibacillus sp. , Veillonella sp. , Bifidobacterium sp. , Bacillus subtilis and Acidaminococcus sp ., for modulating one or more metabolites in a subject, wherein said composition is suitable for consumption by a mammal.
  2. 2. The use according to paragraph 1, characterized in that said composition is a pharmaceutical composition.
  3. 3. The use according to claim 1 or 2, characterized in that said composition is intended to modulate one or more metabolites in a human subject.
  4. 4. The use according to claim 1, characterized in that said composition is intended to determine the ability of Gluconacetobacter hansenii , Terrisporobacter glycolicus , Coprococcus sp. , Lactobacillus plantarum , Clostridium butyricum , Paenibacillus sp. , Veillonella sp. , Bifidobacterium sp. , Bacillus subtilis and Acidaminococcus sp . to modulate one or more metabolites in a subject.
  5. 5. The use according to any one of paragraphs 1-4, characterized in that said composition is intended for use in characterizing the metabolome of a subject.
  6. 6. The use according to any one of claims 1-5, characterized in that said composition additionally contains one or more lipopolysaccharides, wherein said one or more lipopolysaccharides are obtained from E. coli .
  7. 7. The use according to claim 6, wherein said one or more lipopolysaccharides are obtained from E. coli 0111.B4.
  8. 8. The use according to any one of claims 1 to 7, characterized in that said composition contains from 10 6 to 10 15 CFU of each of Gluconacetobacter hansenii , Terrisporobacter glycolicus , Coprococcus sp. , Lactobacillus plantarum , Clostridium butyricum , Paenibacillus sp. , Veillonella sp. , Bifidobacterium sp. , Bacillus subtilis and Acidaminococcus sp .
  9. 9. Use of a composition comprising 101 to 1015 CFU of each of seven or more of Gluconacetobacter hansenii , Terrisporobacter glycolicus , Coprococcus sp. , Lactobacillus plantarum , Clostridium butyricum , Paenibacillus sp. , Veillonella sp. , Bifidobacterium sp. , Bacillus subtilis , and Acidaminococcus sp. , for modulating one or more metabolites in a subject.
  10. 10. The use according to paragraph 9, characterized in that said composition contains:
  11. (a) at least eight strains of microorganisms selected from the group consisting of Gluconacetobacter hansenii , Terrisporobacter glycolicus , Coprococcus sp. , Lactobacillus plantarum , Clostridium butyricum , Paenibacillus sp. , Veillonella sp. , Bifidobacterium sp. , Bacillus subtilis and Acidaminococcus sp.;
  12. (b) at least nine strains of microorganisms selected from the group consisting of Gluconacetobacter hansenii , Terrisporobacter glycolicus , Coprococcus sp. , Lactobacillus plantarum , Clostridium butyricum , Paenibacillus sp. , Veillonella sp. , Bifidobacterium sp. , Bacillus subtilis and Acidaminococcus sp.; and/or
  13. (c) Gluconacetobacter hansenii , Terrisporobacter glycolicus , Coprococcus sp. , Lactobacillus plantarum , Clostridium butyricum , Paenibacillus sp. , Veillonella sp. , Bifidobacterium sp. , Bacillus subtilis and Acidaminococcus sp.
  14. 11. The use according to any one of paragraphs 9 or 10, characterized in that the said composition is additionally suitable for use:
  15. (a) to modulate one or more metabolites in a human subject;
  16. (b) to determine the ability of one or more strains of microorganisms to modulate one or more metabolites in a human subject; or
  17. (c) to characterize the metabolome of a human subject.
  18. 12. The use according to any one of paragraphs 1-11, characterized in that said composition is an ingestible agent, and wherein said ingestible agent is a food product, a beverage, or a pharmaceutical composition.

Description

[0001] This application claims priority to U.S. Provisional Patent Application No. 63/077,544, filed September 11, 2020, the contents of which are incorporated herein by reference in their entirety. LEVEL OF TECHNOLOGY [0002] Generally, the metabolome refers to the metabolites present in an organism, cell, or tissue. Levels of one or more metabolites present in an organism, cell, or tissue may be associated with specific diseases, disorders, or conditions. SUMMARY OF THE INVENTION [0003] The present invention provides an understanding that the compositions described herein can be used to modulate the metabolome of a subject (e.g., a mammal (e.g., a human, a mouse, etc.)). Among other things, the present invention describes technologies that can be used to evaluate the effects of administering compositions (e.g., microbiome compositions) to a subject and to identify or characterize the effects and/or modulation of metabolite levels or the subject's metabolome upon administration of such compositions. In some embodiments, the metabolites that can be modulated may be associated with certain diseases, disorders, or conditions. In some embodiments, such technologies may be useful for detecting differences in metabolite levels in a particular subject (e.g., a patient) or population (e.g., before and after administration of the disclosed compositions). Accordingly, the present disclosure also provides technologies that may be useful for identifying and/or assessing the nature and impact of the disclosed compositions in specific subjects (e.g., patients) and/or populations and, thereby, provide subject-specific information about how the metabolome (e.g., one or more metabolite levels) of individual subjects differentially impacts their health conditions. For example, in some embodiments, the technologies provided herein may be useful for identifying diseases, disorders, or conditions to which a subject may be predisposed based on the metabolome in samples of a particular subject, and for treating and/or preventing such diseases, disorders, or conditions by administering the disclosed compositions (e.g., to modulate the subject's metabolome). Thus, the technologies described herein may be useful as diagnostic tools for screening for certain diseases, disorders, or conditions, as well as for treating and/or preventing such diseases, disorders, or conditions. [0004] Among other things, the present disclosure provides a method comprising determining the level of one or more metabolites in a sample obtained from a subject. In some embodiments, the subject has received a composition comprising one or more strains of microorganisms. In some embodiments, the subject has received a composition comprising one or more lipopolysaccharides. In some embodiments, the subject has received a composition comprising one or more strains of microorganisms and a composition comprising one or more lipopolysaccharides. In some embodiments, the subject has received a composition comprising one or more strains of microorganisms and one or more lipopolysaccharides. [0005] In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. In some embodiments, the subject suffers from or is at risk of developing a disease, disorder, or condition. [0006] In some embodiments, one or more strains of microorganisms are members of the mammalian microbiome. In some embodiments, one or more strains of microorganisms are members of the human microbiome. In some embodiments, one or more strains of microorganisms are members of the microbiome of a subject. [0007] In some embodiments, one or more strains of microorganisms are selected from TABLE 5. [0008] In some embodiments, the one or more strains of microorganisms are Gluconacetobacter hansenii, Terrisporobacter gfycolicus, Coprococcus sp., Lactobacillus plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium sp., Bacillus subtilis, Acidaminococcus sp., or a combination thereof. In some embodiments, the composition comprises or consists of Gluconacetobacter hansenii, Terrisporobacter gfycolicus, Coprococcus sp., Lactobacillus plantarum, Clostridium butyricum, Paenibacillus sp., Veillonella sp., Bifidobacterium sp., Bacillus subtilis, and Acidaminococcus sp. [0009] In some embodiments, the composition comprises two or more strains of microorganisms. In some embodiments, the composition comprises five or more strains of microorganisms. In some embodiments, the composition comprises ten or more strains of microorganisms. [0010] In some embodiments, one or more lipopolysaccharides are obtained from Escherichia coli, Salmonella sp., Shigella sp., Pseudomonas sp., Moraxella sp., Helicobacter sp., Stenotrophomonas sp., Bdellovibrio sp., Legionella sp., acetic acid bacteria, cyanobacteria, spirochetes, green sulfur bacteria, green non-sulfur bacteria, or a combination thereof. In some embodiments, one or more lipopolysaccharides are obtained from E. coli.